Trastuzumab rezetecan (SHR-A1811) exhibited a high confirmed objective response rate (ORR) of 91.7% in HER2-high advanced salivary gland carcinoma (SGC).
The agent demonstrated promising efficacy with a 45.5% ORR in HER2-low SGC, a cohort with limited prior treatment options.
The median progression-free survival and overall survival were not reached in the HER2-high cohort, indicating durable responses.
The safety profile was manageable, with predominantly low-grade adverse events and no treatment-related deaths.
